EPAS1 and colitis: Roxadustat improved symptoms in mice by increasing HIF‐2α levels, decreasing inflammatory cytokines, inhibiting M1 macrophage polarization, and enhancing M2 macrophage polarization in colonic tissues, thereby helping to treat colitis.